Novo Nordisk says obesity drug trial confirms weight loss
COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss. Full story

